Digitally Targeted Incentives for Malaria Case Management in Kenya

How to cite

Dieci, Maria; Gertler, Paul; Kolstad, Jonathan; Paramo, Carlos. 2020. "Digitally Targeted Incentives for Malaria Case Management in Kenya." AEA RCT Registry. AEARCTR-0004705. https://doi.org/10.1257/rct.4705-6.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Maria Dieci* , Paul Gertler , Jonathan Kolstad , Carlos Paramo

* Primary investigator

Registry ID
AEARCTR-0004705
DOI
https://doi.org/10.1257/rct.4705-6.0
First registered
Last updated
Status
Completed
Trial dates
2021-06-01 – 2024-01-31
Countries
Kenya ()
Registry record
http://www.socialscienceregistry.org/trials/4705

Abstract

We investigate the impact of targeted subsidies and incentives for malaria rapid diagnostic testing (RDT) and treatment on demand, sales and stocking decisions, and patient health outcomes, using a novel digital platform in Kenya. This study investigates the impact of differentially targeted incentives for malaria rapid diagnostic testing (RDT) and appropriate malaria treatments on RDT uptake and medication targeting. We use a novel digital platform designed for use in a network of private pharmacies in Kenya. We cross-randomize patient subsidies and pharmacy performance incentives and compare their effectiveness to each other and to the status quo in a cluster-randomized control trial. Our findings will contribute to the literature on the use of subsidies, performance incentives, and digital technology on targeted treatments.

Intervention

The four intervention arms are as follows:
1. Control group: pharmacy is an active user of the basic sales and inventory management digital platform, and pharmacy manages own stock of malaria diagnostic tests and treatments
2. Patient subsidy group: In addition to the features present at control pharmacies, the clients who seek care for suspected malaria cases (for themselves or a household member present with them) will be eligible for a subsidized mRDT (90% subsidy) and a subsidized qualified ACT (80% subsidy) conditional on a confirmed positive malaria diagnosis. Pharmacies in this group will register all patients who elect to access these subsidies in the malaria case management digital platform
3. Pharmacy incentive group: In addition to the features present at control pharmacies, the pharmacies will receive an incentive to administer the mRDT (90 Kes), and an additional incentive to prescribe qualified ACTs to malaria-positive patients (80 Kes). Pharmacy staff will receive a 30 Kes incentive for recording transaction information in the malaria case management platform.
4. Combined group: In addition to the features present at control pharmacies, the clients are eligible for discounted mRDTs (60% subsidy) and discounted qualified ACTs conditional on a positive test result (60% subsidy). Pharmacies will receive an incentive to administer the mRDT (20 Kes), and an additional incentive to prescribe qualified ACTs to malaria-positive patients (15 Kes). Pharmacy staff will receive a 30 Kes incentive for recording transaction information in the malaria case management platform.

Experimental design

A sample of 180 eligible pharmacies in malaria-endemic areas in Kenya will be randomized into one of four study arms: (1) a control group, (2) a patient subsidy group, which offers subsidized prices for RDTs and qualified ACTs, (3) a pharmacy incentive group, which provides small financial incentives to pharmacists/attendants for adhering to malaria clinical guidelines when making treatment recommendations to clients, and (4) a hybrid group, which includes both the pharmacy incentive and patient subsidy.

Design details

Randomization method
Stratified randomization will be conducted using the randtreat package in Stata 16.
Randomization unit
Cluster-level randomization at the pharmacy level (stratified by lake endemic county, urbanicity, and malaria sales volumes)
Clusters
180 pharmacies
Observations
14,400 eligible pharmacy clients (3,600 per arm)
Arms
45 sites control, 45 sites patient subsidy, 45 sites pharmacy incentive, 45 sites hybrid patient subsidy & pharmacy incentive
Primary outcomes
The primary endpoints are uptake of malaria diagnostic tests (RDTs) and the proportion of ACTs that are sold to malaria-positive patients as measured through RDT result (appropriate treatment targeting).
Secondary outcomes
Other key endpoints are uptake of WHO-prequalified ACTs and the proportion of antimalarials that are sold to malaria-negative patients as measured through RDT result.

Cited by

No citation data available for this registration yet.

Keywords